Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SLXN | PRESS-RELEASE | bearish | 5/10 | Silexion Therapeutics reported Q2 2026 net loss of $3.6M (vs $2.5M a year ago) and EPS of -$8.50, far below the -$2.12 c | Aug 14, 2026 |
| VVOS | PRESS-RELEASE | neutral | 1/10 | Vivos Therapeutics, Inc announced it will report its Q2 2026 results on August 14, 2026. | Aug 14, 2026 |
| OTLK | 8-K | bearish | 6/10 | Outlook Therapeutics priced a $55.0M registered direct offering of 55,555,556 shares of common stock and accompanying wa | Aug 14, 2026 |
| VTGN | 8-K | bearish | 6/10 | Vistagen reported Q1 FY2027 net loss of $13.0M ($0.30/share), slightly missing the $0.29 consensus. Revenue of $1.5M was | Aug 14, 2026 |
| MBRX | 8-K | bullish | 7/10 | Moleculin Biotech reported Q2 2026 results highlighting positive interim MIRACLE trial data showing complete remission r | Aug 14, 2026 |
| BCAX | PRESS-RELEASE | neutral | 2/10 | Bicara Therapeutics announced an inducement stock option grant to new CFO Jennifer Larson, effective August 12, 2026, as | Aug 14, 2026 |
| CRNX | 8-K | bullish | 6/10 | Vertex's acquisition of Crinetics cleared all major antitrust hurdles: HSR waiting period expired August 12, and approva | Aug 14, 2026 |
| CLYM | 8-K | neutral | 3/10 | Climb Bio announced that the first patient has been dosed in a Phase 2 clinical trial for immunoglobulin A nephropathy ( | Aug 14, 2026 |
| CLNN | 8-K | mixed | 6/10 | Clene reported Q2 2026 results with a net loss of $13.4M ($1.08/share), widening from $7.4M ($0.78/share) a year ago, dr | Aug 14, 2026 |
| VTGN | PRESS-RELEASE | neutral | 4/10 | Vistagen reported Q1 FY2027 results with a net loss of $0.30 per share, beating consensus of -$0.36 by 16.7%, and revenu | Aug 14, 2026 |
| OTLK | 424B5 | bearish | 7/10 | Outlook Therapeutics priced a $55M underwritten public offering of 55.6M shares and 55.6M warrants at $0.99/unit, repres | Aug 14, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 6/10 | TOMI Environmental Solutions reported Q2 2026 revenue of $2.25M (+118% YoY) and EPS of $(0.05), beating consensus of $(0 | Aug 14, 2026 |
| CLNN | PRESS-RELEASE | mixed | 7/10 | Clene reported Q2 2026 results with a GAAP net loss of $13.4M ($1.08/share), significantly missing the $0.37 consensus d | Aug 14, 2026 |
| MBRX | PRESS-RELEASE | mixed | 6/10 | Moleculin Biotech reported Q2 2026 results with a net loss of -$1.40/share, beating the -$1.55 consensus, and highlighte | Aug 14, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K on August 14, 2026, solely to submit an exhibit (Exhibit 99.1) for an 'Applicatio | Aug 14, 2026 |
| BAK | 6-K | bearish | 8/10 | Braskem's Q2 2026 results confirm a deepening liquidity crisis: the auditor's review report includes a material uncertai | Aug 14, 2026 |
| QNCX | 8-K | neutral | 5/10 | Quince Therapeutics reported Q2 2026 results reflecting the transformational acquisition of Orphai Therapeutics and a co | Aug 14, 2026 |
| EVAX | 6-K | neutral | 2/10 | Evaxion A/S filed a Form 6-K on August 14, 2026, announcing that it will release a business update and Q2 2026 financial | Aug 14, 2026 |
| BAK | 6-K | bearish | 7/10 | Braskem reported strong Q2 2026 operational results with Recurring EBITDA of ~$1.0B and net income of $664M, driven by h | Aug 14, 2026 |
| ALLR | PRESS-RELEASE | neutral | 4/10 | Allarity Therapeutics reported Q2 2026 results with a net loss of $3.4M (vs $2.3M in Q2 2025), driven by higher interest | Aug 14, 2026 |
| ANL | 6-K | bullish | 6/10 | Adlai Nortye reported H1 2026 financial results showing a 70.9% reduction in net loss to $5.3M, driven by $13.1M in init | Aug 14, 2026 |
| PMVP | 8-K | neutral | 5/10 | PMV Pharma reported Q2 2026 results with a net loss of $18.1M ($-0.34/share), beating consensus estimates of $-0.38. The | Aug 14, 2026 |
| HELP | PRESS-RELEASE | bullish | 7/10 | Helus Pharma reported Q4 fiscal 2026 (period ended March 31, 2026) EPS of -$1.17, beating consensus of -$1.38 by 15.5%. | Aug 14, 2026 |
| REPL | PRESS-RELEASE | bullish | 7/10 | Replimune reported a modest EPS beat ($-0.72 vs $-0.77 consensus) for Q1 FY2026, but the headline is the FDA accelerated | Aug 14, 2026 |
| QNCX | PRESS-RELEASE | bullish | 6/10 | Quince Therapeutics reported Q2 2026 results highlighting a strengthened balance sheet with $116M cash following the Orp | Aug 14, 2026 |
| GTBP | PRESS-RELEASE | bearish | 5/10 | GT Biopharma reported Q2 2026 EPS of -$0.11, missing consensus of -$0.08 by 37.5%, with no revenue. Cash runway of $5.1M | Aug 14, 2026 |
| PMVP | PRESS-RELEASE | bullish | 6/10 | PMV Pharma reported Q2 2026 EPS of -$0.34, beating the -$0.38 consensus by 10.5%, and completed enrollment for the prima | Aug 14, 2026 |
| EVAX | PRESS-RELEASE | neutral | 1/10 | Evaxion announced it will report its Q2 2026 results on August 20, 2026. | Aug 14, 2026 |
| GALT | PRESS-RELEASE | bullish | 8/10 | Galectin Therapeutics reported Q2 2026 net loss of $9.2M ($0.14/share) vs $7.6M ($0.12/share) a year ago, but the headli | Aug 14, 2026 |
| HURA | PRESS-RELEASE | neutral | 3/10 | TuHURA Biosciences reported Q2 2026 financial results with no revenue or EPS, as the company remains pre-revenue. Cash s | Aug 14, 2026 |